206 related articles for article (PubMed ID: 27591880)
21. Protective effects of oxymatrine on experimental diabetic nephropathy.
Guo C; Han F; Zhang C; Xiao W; Yang Z
Planta Med; 2014 Mar; 80(4):269-76. PubMed ID: 24535719
[TBL] [Abstract][Full Text] [Related]
22. Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data From a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes.
Cooper ME; Perkovic V; McGill JB; Groop PH; Wanner C; Rosenstock J; Hehnke U; Woerle HJ; von Eynatten M
Am J Kidney Dis; 2015 Sep; 66(3):441-9. PubMed ID: 25960304
[TBL] [Abstract][Full Text] [Related]
23. Animal models of diabetic nephropathy.
Mauer SM; Steffes MW; Brown DM
Adv Nephrol Necker Hosp; 1979; 8():23-42. PubMed ID: 115242
[No Abstract] [Full Text] [Related]
24. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy.
Alter ML; Ott IM; von Websky K; Tsuprykov O; Sharkovska Y; Krause-Relle K; Raila J; Henze A; Klein T; Hocher B
Kidney Blood Press Res; 2012; 36(1):119-30. PubMed ID: 23171828
[TBL] [Abstract][Full Text] [Related]
25. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
26. The cyclin kinase inhibitor p21WAF1/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy.
Al-Douahji M; Brugarolas J; Brown PA; Stehman-Breen CO; Alpers CE; Shankland SJ
Kidney Int; 1999 Nov; 56(5):1691-9. PubMed ID: 10571777
[TBL] [Abstract][Full Text] [Related]
27. Studies of kidney and muscle biopsy specimens from identical twins discordant for type I diabetes mellitus.
Steffes MW; Sutherland DE; Goetz FC; Rich SS; Mauer SM
N Engl J Med; 1985 May; 312(20):1282-7. PubMed ID: 4039409
[TBL] [Abstract][Full Text] [Related]
28. Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis.
Adhikari J; Hirai T; Kawakita E; Iwai K; Koya D; Kanasaki K
J Diabetes Investig; 2023 Jul; 14(7):844-855. PubMed ID: 37092329
[TBL] [Abstract][Full Text] [Related]
29. Effect of aspirin on experimental diabetic nephropathy.
Moel DI; Safirstein RL; McEvoy RC; Hsueh W
J Lab Clin Med; 1987 Sep; 110(3):300-7. PubMed ID: 3475395
[TBL] [Abstract][Full Text] [Related]
30. Disparate effects of castration on renal structure and function in the streptozotocin diabetic rat.
Bach LA; Cooper ME; Vranes D; Allen TJ; Rumble J; Jerums G
Diabetes Res; 1994; 27(1):27-38. PubMed ID: 7648794
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin prevents early steps of the development of diabetic nephropathy in rats.
Yang Y; Wang J; Qin L; Shou Z; Zhao J; Wang H; Chen Y; Chen J
Am J Nephrol; 2007; 27(5):495-502. PubMed ID: 17671379
[TBL] [Abstract][Full Text] [Related]
32. Three-dimensional architecture of glomerular extracellular matrices in diabetic glomerulosclerosis.
Makino H; Nishimura S; Haramoto T; Yamasaki Y; Ikeda S; Ota Z
J Diabet Complications; 1991; 5(2-3):124-5. PubMed ID: 1770017
[TBL] [Abstract][Full Text] [Related]
33. Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen.
Kanasaki K; Shi S; Kanasaki M; He J; Nagai T; Nakamura Y; Ishigaki Y; Kitada M; Srivastava SP; Koya D
Diabetes; 2014 Jun; 63(6):2120-31. PubMed ID: 24574044
[TBL] [Abstract][Full Text] [Related]
34. Pathological changes in streptozotocin induced diabetes mellitus in the rat.
Yong LC; Bleasel AF
Exp Pathol; 1986; 30(2):97-107. PubMed ID: 3780940
[TBL] [Abstract][Full Text] [Related]
35. Interactions of DPP-4 and integrin β1 influences endothelial-to-mesenchymal transition.
Shi S; Srivastava SP; Kanasaki M; He J; Kitada M; Nagai T; Nitta K; Takagi S; Kanasaki K; Koya D
Kidney Int; 2015 Sep; 88(3):479-89. PubMed ID: 25830763
[TBL] [Abstract][Full Text] [Related]
36. Novel findings of secreted cyclophilin A in diabetic nephropathy and its association with renal protection of dipeptidyl peptidase 4 inhibitor.
Tsai SF; Hsieh CC; Wu MJ; Chen CH; Lin TH; Hsieh M
Clin Chim Acta; 2016 Dec; 463():181-192. PubMed ID: 27823952
[TBL] [Abstract][Full Text] [Related]
37. Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis.
Nakashima S; Matsui T; Takeuchi M; Yamagishi SI
Horm Metab Res; 2014 Sep; 46(10):717-21. PubMed ID: 24710699
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic effect of Acacia nilotica pods extract on streptozotocin induced diabetic nephropathy in rat.
Omara EA; Nada SA; Farrag AR; Sharaf WM; El-Toumy SA
Phytomedicine; 2012 Sep; 19(12):1059-67. PubMed ID: 22884305
[TBL] [Abstract][Full Text] [Related]
39. The KKAy mouse: a model for the rapid development of glomerular capillary basement membrane thickening.
Diani AR; Sawada GA; Zhang NY; Wyse BM; Connell CL; Vidmar TJ; Connell MA
Blood Vessels; 1987; 24(6):297-303. PubMed ID: 3651618
[TBL] [Abstract][Full Text] [Related]
40. Diabetic glomerulopathy in man and experimental animal models.
Steffes MW; Mauer SM
Int Rev Exp Pathol; 1984; 26():147-75. PubMed ID: 6400512
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
